Wiener klinische Wochenschrift
-
Wien. Klin. Wochenschr. · Jan 2022
Observational StudyCirculating bioactive sclerostin levels in an Austrian population-based cohort.
Circulating serum sclerostin levels are supposed to give a good estimation of the levels of this negative regulator of bone mass within bone. Most studies evaluating total serum sclerostin found different levels in males compared to females and in older compared to younger subjects. Besides an ELISA detecting total sclerostin an ELISA determining bioactive sclerostin has been developed. The aim of this study was to investigate serum levels of bioactive sclerostin in an Austrian population-based cohort. ⋯ Using the ELISA detecting bioactive sclerostin our results are consistent with data in the literature obtained by different sclerostin assays. The determination of sclerostin concentrations in peripheral blood thus appears to be a robust parameter of bone metabolism.
-
Wien. Klin. Wochenschr. · Jan 2022
Impact of rapid correction of vitamin D deficiency in asthmatic patients.
Asthma is one of the most common chronic diseases, which is a growing public health concern worldwide. In recent years, there has been an increasing number of interests in the relationship between vitamin D level and asthma control. Hence, the objective of this study was to assess the effect of high doses of vitamin D3 injection on asthmatic patient's respiratory condition and quality of life. ⋯ Our findings suggest that screening for serum 25-(OH) D3 deficiency is important in asthmatic patients and correction of this deficiency with high doses of vitamin D3 injection may lead to improvement in pulmonary function, symptoms and quality of life (QOL).
-
Wien. Klin. Wochenschr. · Jan 2022
Clinical risk factors for recurrence of pelvic organ prolapse after primary native tissue prolapse repair.
To define potential risk factors for recurrence of prolapse. ⋯ Initial proper preoperative counseling is of particular importance to modulate patients' expectations after prolapse surgery.
-
Wien. Klin. Wochenschr. · Jan 2022
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.